COVID-19 Impact on Global Selective Cox-2 Inhibitors Market Size, Status and Forecast 2020-2026
This report focuses on the global Selective Cox-2 Inhibitors status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Selective Cox-2 Inhibitors development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study
The key players covered in this study
- Boehringer-Ingelheim
- TerSera Therapeutics
- Iroko Pharmaceuticals
- Apotex
- Yung Shin Pharmaceutical
- Breckenridge Pharmaceutical
- Meda Pharmaceuticals
- Cipla
- Glenmark Pharmaceuticals
- Teva
- PuraCap Pharmaceutical
- Almirall Limited
- Lupin Pharmaceuticals
- Aurobindo Pharma
- Pfizer
- Mylan
- Takeda
- Bayer
- Novacap
- Abbott
- Geri-Care
- Perrigo
- Kopran
- Merck
- Hengrui pharmaceutical
- Kelun Group
- Qilu Pharmaceutical
- Taro Pharmaceuticals
- Meloxicam
- Celecoxib
- Etoricoxib
- Imrecoxib
- Etodolac
- Parecoxib
- Other
- Rheumatoid Arthritis
- Osteoarthritis
- Spondylosis Chronica Ankylopoietica
- Other
- North America
- Europe
- China
- Japan
- Southeast Asia
- India
- Central & South America
- To analyze global Selective Cox-2 Inhibitors status, future forecast, growth opportunity, key market and key players.
- To present the Selective Cox-2 Inhibitors development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
- To strategically profile the key players and comprehensively analyze their development plan and strategies.
- To define, describe and forecast the market by type, market and key regions.
- History Year: 2015-2019
- Base Year: 2019
- Estimated Year: 2020
- Forecast Year 2020 to 2026
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Selective Cox-2 Inhibitors Revenue
1.4 Market Analysis by Type
1.4.1 Global Selective Cox-2 Inhibitors Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Meloxicam
1.4.3 Celecoxib
1.4.4 Etoricoxib
1.4.5 Imrecoxib
1.4.6 Etodolac
1.4.7 Parecoxib
1.4.8 Other
1.5 Market by Application
1.5.1 Global Selective Cox-2 Inhibitors Market Share by Application: 2020 VS 2026
1.5.2 Rheumatoid Arthritis
1.5.3 Osteoarthritis
1.5.4 Spondylosis Chronica Ankylopoietica
1.5.5 Other
1.6 Coronavirus Disease 2019 (Covid-19): Selective Cox-2 Inhibitors Industry Impact
1.6.1 How the Covid-19 is Affecting the Selective Cox-2 Inhibitors Industry
1.6.1.1 Selective Cox-2 Inhibitors Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Selective Cox-2 Inhibitors Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Selective Cox-2 Inhibitors Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Selective Cox-2 Inhibitors Market Perspective (2015-2026)
2.2 Selective Cox-2 Inhibitors Growth Trends by Regions
2.2.1 Selective Cox-2 Inhibitors Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Selective Cox-2 Inhibitors Historic Market Share by Regions (2015-2020)
2.2.3 Selective Cox-2 Inhibitors Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Selective Cox-2 Inhibitors Market Growth Strategy
2.3.6 Primary Interviews with Key Selective Cox-2 Inhibitors Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Selective Cox-2 Inhibitors Players by Market Size
3.1.1 Global Top Selective Cox-2 Inhibitors Players by Revenue (2015-2020)
3.1.2 Global Selective Cox-2 Inhibitors Revenue Market Share by Players (2015-2020)
3.1.3 Global Selective Cox-2 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Selective Cox-2 Inhibitors Market Concentration Ratio
3.2.1 Global Selective Cox-2 Inhibitors Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Selective Cox-2 Inhibitors Revenue in 2019
3.3 Selective Cox-2 Inhibitors Key Players Head office and Area Served
3.4 Key Players Selective Cox-2 Inhibitors Product Solution and Service
3.5 Date of Enter into Selective Cox-2 Inhibitors Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Selective Cox-2 Inhibitors Historic Market Size by Type (2015-2020)
4.2 Global Selective Cox-2 Inhibitors Forecasted Market Size by Type (2021-2026)
5 SELECTIVE COX-2 INHIBITORS BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Selective Cox-2 Inhibitors Market Size by Application (2015-2020)
5.2 Global Selective Cox-2 Inhibitors Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Selective Cox-2 Inhibitors Market Size (2015-2020)
6.2 Selective Cox-2 Inhibitors Key Players in North America (2019-2020)
6.3 North America Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
6.4 North America Selective Cox-2 Inhibitors Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Selective Cox-2 Inhibitors Market Size (2015-2020)
7.2 Selective Cox-2 Inhibitors Key Players in Europe (2019-2020)
7.3 Europe Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
7.4 Europe Selective Cox-2 Inhibitors Market Size by Application (2015-2020)
8 CHINA
8.1 China Selective Cox-2 Inhibitors Market Size (2015-2020)
8.2 Selective Cox-2 Inhibitors Key Players in China (2019-2020)
8.3 China Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
8.4 China Selective Cox-2 Inhibitors Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan Selective Cox-2 Inhibitors Market Size (2015-2020)
9.2 Selective Cox-2 Inhibitors Key Players in Japan (2019-2020)
9.3 Japan Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
9.4 Japan Selective Cox-2 Inhibitors Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia Selective Cox-2 Inhibitors Market Size (2015-2020)
10.2 Selective Cox-2 Inhibitors Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
10.4 Southeast Asia Selective Cox-2 Inhibitors Market Size by Application (2015-2020)
11 INDIA
11.1 India Selective Cox-2 Inhibitors Market Size (2015-2020)
11.2 Selective Cox-2 Inhibitors Key Players in India (2019-2020)
11.3 India Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
11.4 India Selective Cox-2 Inhibitors Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America Selective Cox-2 Inhibitors Market Size (2015-2020)
12.2 Selective Cox-2 Inhibitors Key Players in Central & South America (2019-2020)
12.3 Central & South America Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
12.4 Central & South America Selective Cox-2 Inhibitors Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Boehringer-Ingelheim
13.1.1 Boehringer-Ingelheim Company Details
13.1.2 Boehringer-Ingelheim Business Overview and Its Total Revenue
13.1.3 Boehringer-Ingelheim Selective Cox-2 Inhibitors Introduction
13.1.4 Boehringer-Ingelheim Revenue in Selective Cox-2 Inhibitors Business (2015-2020))
13.1.5 Boehringer-Ingelheim Recent Development
13.2 TerSera Therapeutics
13.2.1 TerSera Therapeutics Company Details
13.2.2 TerSera Therapeutics Business Overview and Its Total Revenue
13.2.3 TerSera Therapeutics Selective Cox-2 Inhibitors Introduction
13.2.4 TerSera Therapeutics Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
13.2.5 TerSera Therapeutics Recent Development
13.3 Iroko Pharmaceuticals
13.3.1 Iroko Pharmaceuticals Company Details
13.3.2 Iroko Pharmaceuticals Business Overview and Its Total Revenue
13.3.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Introduction
13.3.4 Iroko Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
13.3.5 Iroko Pharmaceuticals Recent Development
13.4 Apotex
13.4.1 Apotex Company Details
13.4.2 Apotex Business Overview and Its Total Revenue
13.4.3 Apotex Selective Cox-2 Inhibitors Introduction
13.4.4 Apotex Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
13.4.5 Apotex Recent Development
13.5 Yung Shin Pharmaceutical
13.5.1 Yung Shin Pharmaceutical Company Details
13.5.2 Yung Shin Pharmaceutical Business Overview and Its Total Revenue
13.5.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Introduction
13.5.4 Yung Shin Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
13.5.5 Yung Shin Pharmaceutical Recent Development
13.6 Breckenridge Pharmaceutical
13.6.1 Breckenridge Pharmaceutical Company Details
13.6.2 Breckenridge Pharmaceutical Business Overview and Its Total Revenue
13.6.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Introduction
13.6.4 Breckenridge Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
13.6.5 Breckenridge Pharmaceutical Recent Development
13.7 Meda Pharmaceuticals
13.7.1 Meda Pharmaceuticals Company Details
13.7.2 Meda Pharmaceuticals Business Overview and Its Total Revenue
13.7.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Introduction
13.7.4 Meda Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
13.7.5 Meda Pharmaceuticals Recent Development
13.8 Cipla
13.8.1 Cipla Company Details
13.8.2 Cipla Business Overview and Its Total Revenue
13.8.3 Cipla Selective Cox-2 Inhibitors Introduction
13.8.4 Cipla Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
13.8.5 Cipla Recent Development
13.9 Glenmark Pharmaceuticals
13.9.1 Glenmark Pharmaceuticals Company Details
13.9.2 Glenmark Pharmaceuticals Business Overview and Its Total Revenue
13.9.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Introduction
13.9.4 Glenmark Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
13.9.5 Glenmark Pharmaceuticals Recent Development
13.10 Teva
13.10.1 Teva Company Details
13.10.2 Teva Business Overview and Its Total Revenue
13.10.3 Teva Selective Cox-2 Inhibitors Introduction
13.10.4 Teva Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
13.10.5 Teva Recent Development
13.11 PuraCap Pharmaceutical
10.11.1 PuraCap Pharmaceutical Company Details
10.11.2 PuraCap Pharmaceutical Business Overview and Its Total Revenue
10.11.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Introduction
10.11.4 PuraCap Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.11.5 PuraCap Pharmaceutical Recent Development
13.12 Almirall Limited
10.12.1 Almirall Limited Company Details
10.12.2 Almirall Limited Business Overview and Its Total Revenue
10.12.3 Almirall Limited Selective Cox-2 Inhibitors Introduction
10.12.4 Almirall Limited Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.12.5 Almirall Limited Recent Development
13.13 Lupin Pharmaceuticals
10.13.1 Lupin Pharmaceuticals Company Details
10.13.2 Lupin Pharmaceuticals Business Overview and Its Total Revenue
10.13.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Introduction
10.13.4 Lupin Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.13.5 Lupin Pharmaceuticals Recent Development
13.14 Aurobindo Pharma
10.14.1 Aurobindo Pharma Company Details
10.14.2 Aurobindo Pharma Business Overview and Its Total Revenue
10.14.3 Aurobindo Pharma Selective Cox-2 Inhibitors Introduction
10.14.4 Aurobindo Pharma Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.14.5 Aurobindo Pharma Recent Development
13.15 Pfizer
10.15.1 Pfizer Company Details
10.15.2 Pfizer Business Overview and Its Total Revenue
10.15.3 Pfizer Selective Cox-2 Inhibitors Introduction
10.15.4 Pfizer Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.15.5 Pfizer Recent Development
13.16 Mylan
10.16.1 Mylan Company Details
10.16.2 Mylan Business Overview and Its Total Revenue
10.16.3 Mylan Selective Cox-2 Inhibitors Introduction
10.16.4 Mylan Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.16.5 Mylan Recent Development
13.17 Takeda
10.17.1 Takeda Company Details
10.17.2 Takeda Business Overview and Its Total Revenue
10.17.3 Takeda Selective Cox-2 Inhibitors Introduction
10.17.4 Takeda Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.17.5 Takeda Recent Development
13.18 Bayer
10.18.1 Bayer Company Details
10.18.2 Bayer Business Overview and Its Total Revenue
10.18.3 Bayer Selective Cox-2 Inhibitors Introduction
10.18.4 Bayer Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.18.5 Bayer Recent Development
13.19 Novacap
10.19.1 Novacap Company Details
10.19.2 Novacap Business Overview and Its Total Revenue
10.19.3 Novacap Selective Cox-2 Inhibitors Introduction
10.19.4 Novacap Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.19.5 Novacap Recent Development
13.20 Abbott
10.20.1 Abbott Company Details
10.20.2 Abbott Business Overview and Its Total Revenue
10.20.3 Abbott Selective Cox-2 Inhibitors Introduction
10.20.4 Abbott Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.20.5 Abbott Recent Development
13.21 Geri-Care
10.21.1 Geri-Care Company Details
10.21.2 Geri-Care Business Overview and Its Total Revenue
10.21.3 Geri-Care Selective Cox-2 Inhibitors Introduction
10.21.4 Geri-Care Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.21.5 Geri-Care Recent Development
13.22 Perrigo
10.22.1 Perrigo Company Details
10.22.2 Perrigo Business Overview and Its Total Revenue
10.22.3 Perrigo Selective Cox-2 Inhibitors Introduction
10.22.4 Perrigo Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.22.5 Perrigo Recent Development
13.23 Kopran
10.23.1 Kopran Company Details
10.23.2 Kopran Business Overview and Its Total Revenue
10.23.3 Kopran Selective Cox-2 Inhibitors Introduction
10.23.4 Kopran Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.23.5 Kopran Recent Development
13.24 Merck
10.24.1 Merck Company Details
10.24.2 Merck Business Overview and Its Total Revenue
10.24.3 Merck Selective Cox-2 Inhibitors Introduction
10.24.4 Merck Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.24.5 Merck Recent Development
13.25 Hengrui pharmaceutical
10.25.1 Hengrui pharmaceutical Company Details
10.25.2 Hengrui pharmaceutical Business Overview and Its Total Revenue
10.25.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Introduction
10.25.4 Hengrui pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.25.5 Hengrui pharmaceutical Recent Development
13.26 Kelun Group
10.26.1 Kelun Group Company Details
10.26.2 Kelun Group Business Overview and Its Total Revenue
10.26.3 Kelun Group Selective Cox-2 Inhibitors Introduction
10.26.4 Kelun Group Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.26.5 Kelun Group Recent Development
13.27 Qilu Pharmaceutical
10.27.1 Qilu Pharmaceutical Company Details
10.27.2 Qilu Pharmaceutical Business Overview and Its Total Revenue
10.27.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Introduction
10.27.4 Qilu Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.27.5 Qilu Pharmaceutical Recent Development
13.28 Taro Pharmaceuticals
10.28.1 Taro Pharmaceuticals Company Details
10.28.2 Taro Pharmaceuticals Business Overview and Its Total Revenue
10.28.3 Taro Pharmaceuticals Selective Cox-2 Inhibitors Introduction
10.28.4 Taro Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.28.5 Taro Pharmaceuticals Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Selective Cox-2 Inhibitors Revenue
1.4 Market Analysis by Type
1.4.1 Global Selective Cox-2 Inhibitors Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Meloxicam
1.4.3 Celecoxib
1.4.4 Etoricoxib
1.4.5 Imrecoxib
1.4.6 Etodolac
1.4.7 Parecoxib
1.4.8 Other
1.5 Market by Application
1.5.1 Global Selective Cox-2 Inhibitors Market Share by Application: 2020 VS 2026
1.5.2 Rheumatoid Arthritis
1.5.3 Osteoarthritis
1.5.4 Spondylosis Chronica Ankylopoietica
1.5.5 Other
1.6 Coronavirus Disease 2019 (Covid-19): Selective Cox-2 Inhibitors Industry Impact
1.6.1 How the Covid-19 is Affecting the Selective Cox-2 Inhibitors Industry
1.6.1.1 Selective Cox-2 Inhibitors Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Selective Cox-2 Inhibitors Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Selective Cox-2 Inhibitors Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Selective Cox-2 Inhibitors Market Perspective (2015-2026)
2.2 Selective Cox-2 Inhibitors Growth Trends by Regions
2.2.1 Selective Cox-2 Inhibitors Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Selective Cox-2 Inhibitors Historic Market Share by Regions (2015-2020)
2.2.3 Selective Cox-2 Inhibitors Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Selective Cox-2 Inhibitors Market Growth Strategy
2.3.6 Primary Interviews with Key Selective Cox-2 Inhibitors Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Selective Cox-2 Inhibitors Players by Market Size
3.1.1 Global Top Selective Cox-2 Inhibitors Players by Revenue (2015-2020)
3.1.2 Global Selective Cox-2 Inhibitors Revenue Market Share by Players (2015-2020)
3.1.3 Global Selective Cox-2 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Selective Cox-2 Inhibitors Market Concentration Ratio
3.2.1 Global Selective Cox-2 Inhibitors Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Selective Cox-2 Inhibitors Revenue in 2019
3.3 Selective Cox-2 Inhibitors Key Players Head office and Area Served
3.4 Key Players Selective Cox-2 Inhibitors Product Solution and Service
3.5 Date of Enter into Selective Cox-2 Inhibitors Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Selective Cox-2 Inhibitors Historic Market Size by Type (2015-2020)
4.2 Global Selective Cox-2 Inhibitors Forecasted Market Size by Type (2021-2026)
5 SELECTIVE COX-2 INHIBITORS BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Selective Cox-2 Inhibitors Market Size by Application (2015-2020)
5.2 Global Selective Cox-2 Inhibitors Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Selective Cox-2 Inhibitors Market Size (2015-2020)
6.2 Selective Cox-2 Inhibitors Key Players in North America (2019-2020)
6.3 North America Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
6.4 North America Selective Cox-2 Inhibitors Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Selective Cox-2 Inhibitors Market Size (2015-2020)
7.2 Selective Cox-2 Inhibitors Key Players in Europe (2019-2020)
7.3 Europe Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
7.4 Europe Selective Cox-2 Inhibitors Market Size by Application (2015-2020)
8 CHINA
8.1 China Selective Cox-2 Inhibitors Market Size (2015-2020)
8.2 Selective Cox-2 Inhibitors Key Players in China (2019-2020)
8.3 China Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
8.4 China Selective Cox-2 Inhibitors Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan Selective Cox-2 Inhibitors Market Size (2015-2020)
9.2 Selective Cox-2 Inhibitors Key Players in Japan (2019-2020)
9.3 Japan Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
9.4 Japan Selective Cox-2 Inhibitors Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia Selective Cox-2 Inhibitors Market Size (2015-2020)
10.2 Selective Cox-2 Inhibitors Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
10.4 Southeast Asia Selective Cox-2 Inhibitors Market Size by Application (2015-2020)
11 INDIA
11.1 India Selective Cox-2 Inhibitors Market Size (2015-2020)
11.2 Selective Cox-2 Inhibitors Key Players in India (2019-2020)
11.3 India Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
11.4 India Selective Cox-2 Inhibitors Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America Selective Cox-2 Inhibitors Market Size (2015-2020)
12.2 Selective Cox-2 Inhibitors Key Players in Central & South America (2019-2020)
12.3 Central & South America Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
12.4 Central & South America Selective Cox-2 Inhibitors Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Boehringer-Ingelheim
13.1.1 Boehringer-Ingelheim Company Details
13.1.2 Boehringer-Ingelheim Business Overview and Its Total Revenue
13.1.3 Boehringer-Ingelheim Selective Cox-2 Inhibitors Introduction
13.1.4 Boehringer-Ingelheim Revenue in Selective Cox-2 Inhibitors Business (2015-2020))
13.1.5 Boehringer-Ingelheim Recent Development
13.2 TerSera Therapeutics
13.2.1 TerSera Therapeutics Company Details
13.2.2 TerSera Therapeutics Business Overview and Its Total Revenue
13.2.3 TerSera Therapeutics Selective Cox-2 Inhibitors Introduction
13.2.4 TerSera Therapeutics Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
13.2.5 TerSera Therapeutics Recent Development
13.3 Iroko Pharmaceuticals
13.3.1 Iroko Pharmaceuticals Company Details
13.3.2 Iroko Pharmaceuticals Business Overview and Its Total Revenue
13.3.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Introduction
13.3.4 Iroko Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
13.3.5 Iroko Pharmaceuticals Recent Development
13.4 Apotex
13.4.1 Apotex Company Details
13.4.2 Apotex Business Overview and Its Total Revenue
13.4.3 Apotex Selective Cox-2 Inhibitors Introduction
13.4.4 Apotex Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
13.4.5 Apotex Recent Development
13.5 Yung Shin Pharmaceutical
13.5.1 Yung Shin Pharmaceutical Company Details
13.5.2 Yung Shin Pharmaceutical Business Overview and Its Total Revenue
13.5.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Introduction
13.5.4 Yung Shin Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
13.5.5 Yung Shin Pharmaceutical Recent Development
13.6 Breckenridge Pharmaceutical
13.6.1 Breckenridge Pharmaceutical Company Details
13.6.2 Breckenridge Pharmaceutical Business Overview and Its Total Revenue
13.6.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Introduction
13.6.4 Breckenridge Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
13.6.5 Breckenridge Pharmaceutical Recent Development
13.7 Meda Pharmaceuticals
13.7.1 Meda Pharmaceuticals Company Details
13.7.2 Meda Pharmaceuticals Business Overview and Its Total Revenue
13.7.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Introduction
13.7.4 Meda Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
13.7.5 Meda Pharmaceuticals Recent Development
13.8 Cipla
13.8.1 Cipla Company Details
13.8.2 Cipla Business Overview and Its Total Revenue
13.8.3 Cipla Selective Cox-2 Inhibitors Introduction
13.8.4 Cipla Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
13.8.5 Cipla Recent Development
13.9 Glenmark Pharmaceuticals
13.9.1 Glenmark Pharmaceuticals Company Details
13.9.2 Glenmark Pharmaceuticals Business Overview and Its Total Revenue
13.9.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Introduction
13.9.4 Glenmark Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
13.9.5 Glenmark Pharmaceuticals Recent Development
13.10 Teva
13.10.1 Teva Company Details
13.10.2 Teva Business Overview and Its Total Revenue
13.10.3 Teva Selective Cox-2 Inhibitors Introduction
13.10.4 Teva Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
13.10.5 Teva Recent Development
13.11 PuraCap Pharmaceutical
10.11.1 PuraCap Pharmaceutical Company Details
10.11.2 PuraCap Pharmaceutical Business Overview and Its Total Revenue
10.11.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Introduction
10.11.4 PuraCap Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.11.5 PuraCap Pharmaceutical Recent Development
13.12 Almirall Limited
10.12.1 Almirall Limited Company Details
10.12.2 Almirall Limited Business Overview and Its Total Revenue
10.12.3 Almirall Limited Selective Cox-2 Inhibitors Introduction
10.12.4 Almirall Limited Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.12.5 Almirall Limited Recent Development
13.13 Lupin Pharmaceuticals
10.13.1 Lupin Pharmaceuticals Company Details
10.13.2 Lupin Pharmaceuticals Business Overview and Its Total Revenue
10.13.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Introduction
10.13.4 Lupin Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.13.5 Lupin Pharmaceuticals Recent Development
13.14 Aurobindo Pharma
10.14.1 Aurobindo Pharma Company Details
10.14.2 Aurobindo Pharma Business Overview and Its Total Revenue
10.14.3 Aurobindo Pharma Selective Cox-2 Inhibitors Introduction
10.14.4 Aurobindo Pharma Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.14.5 Aurobindo Pharma Recent Development
13.15 Pfizer
10.15.1 Pfizer Company Details
10.15.2 Pfizer Business Overview and Its Total Revenue
10.15.3 Pfizer Selective Cox-2 Inhibitors Introduction
10.15.4 Pfizer Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.15.5 Pfizer Recent Development
13.16 Mylan
10.16.1 Mylan Company Details
10.16.2 Mylan Business Overview and Its Total Revenue
10.16.3 Mylan Selective Cox-2 Inhibitors Introduction
10.16.4 Mylan Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.16.5 Mylan Recent Development
13.17 Takeda
10.17.1 Takeda Company Details
10.17.2 Takeda Business Overview and Its Total Revenue
10.17.3 Takeda Selective Cox-2 Inhibitors Introduction
10.17.4 Takeda Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.17.5 Takeda Recent Development
13.18 Bayer
10.18.1 Bayer Company Details
10.18.2 Bayer Business Overview and Its Total Revenue
10.18.3 Bayer Selective Cox-2 Inhibitors Introduction
10.18.4 Bayer Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.18.5 Bayer Recent Development
13.19 Novacap
10.19.1 Novacap Company Details
10.19.2 Novacap Business Overview and Its Total Revenue
10.19.3 Novacap Selective Cox-2 Inhibitors Introduction
10.19.4 Novacap Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.19.5 Novacap Recent Development
13.20 Abbott
10.20.1 Abbott Company Details
10.20.2 Abbott Business Overview and Its Total Revenue
10.20.3 Abbott Selective Cox-2 Inhibitors Introduction
10.20.4 Abbott Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.20.5 Abbott Recent Development
13.21 Geri-Care
10.21.1 Geri-Care Company Details
10.21.2 Geri-Care Business Overview and Its Total Revenue
10.21.3 Geri-Care Selective Cox-2 Inhibitors Introduction
10.21.4 Geri-Care Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.21.5 Geri-Care Recent Development
13.22 Perrigo
10.22.1 Perrigo Company Details
10.22.2 Perrigo Business Overview and Its Total Revenue
10.22.3 Perrigo Selective Cox-2 Inhibitors Introduction
10.22.4 Perrigo Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.22.5 Perrigo Recent Development
13.23 Kopran
10.23.1 Kopran Company Details
10.23.2 Kopran Business Overview and Its Total Revenue
10.23.3 Kopran Selective Cox-2 Inhibitors Introduction
10.23.4 Kopran Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.23.5 Kopran Recent Development
13.24 Merck
10.24.1 Merck Company Details
10.24.2 Merck Business Overview and Its Total Revenue
10.24.3 Merck Selective Cox-2 Inhibitors Introduction
10.24.4 Merck Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.24.5 Merck Recent Development
13.25 Hengrui pharmaceutical
10.25.1 Hengrui pharmaceutical Company Details
10.25.2 Hengrui pharmaceutical Business Overview and Its Total Revenue
10.25.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Introduction
10.25.4 Hengrui pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.25.5 Hengrui pharmaceutical Recent Development
13.26 Kelun Group
10.26.1 Kelun Group Company Details
10.26.2 Kelun Group Business Overview and Its Total Revenue
10.26.3 Kelun Group Selective Cox-2 Inhibitors Introduction
10.26.4 Kelun Group Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.26.5 Kelun Group Recent Development
13.27 Qilu Pharmaceutical
10.27.1 Qilu Pharmaceutical Company Details
10.27.2 Qilu Pharmaceutical Business Overview and Its Total Revenue
10.27.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Introduction
10.27.4 Qilu Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.27.5 Qilu Pharmaceutical Recent Development
13.28 Taro Pharmaceuticals
10.28.1 Taro Pharmaceuticals Company Details
10.28.2 Taro Pharmaceuticals Business Overview and Its Total Revenue
10.28.3 Taro Pharmaceuticals Selective Cox-2 Inhibitors Introduction
10.28.4 Taro Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
10.28.5 Taro Pharmaceuticals Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
LIST OF TABLES
Table 1. Selective Cox-2 Inhibitors Key Market Segments
Table 2. Key Players Covered: Ranking by Selective Cox-2 Inhibitors Revenue
Table 3. Ranking of Global Top Selective Cox-2 Inhibitors Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Selective Cox-2 Inhibitors Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Meloxicam
Table 6. Key Players of Celecoxib
Table 7. Key Players of Etoricoxib
Table 8. Key Players of Imrecoxib
Table 9. Key Players of Etodolac
Table 10. Key Players of Parecoxib
Table 11. Key Players of Other
Table 12. COVID-19 Impact Global Market: (Four Selective Cox-2 Inhibitors Market Size Forecast Scenarios)
Table 13. Opportunities and Trends for Selective Cox-2 Inhibitors Players in the COVID-19 Landscape
Table 14. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 15. Key Regions/Countries Measures against Covid-19 Impact
Table 16. Proposal for Selective Cox-2 Inhibitors Players to Combat Covid-19 Impact
Table 17. Global Selective Cox-2 Inhibitors Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 18. Global Selective Cox-2 Inhibitors Market Size by Regions (US$ Million): 2020 VS 2026
Table 19. Global Selective Cox-2 Inhibitors Market Size by Regions (2015-2020) (US$ Million)
Table 20. Global Selective Cox-2 Inhibitors Market Share by Regions (2015-2020)
Table 21. Global Selective Cox-2 Inhibitors Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 22. Global Selective Cox-2 Inhibitors Market Share by Regions (2021-2026)
Table 23. Market Top Trends
Table 24. Key Drivers: Impact Analysis
Table 25. Key Challenges
Table 26. Selective Cox-2 Inhibitors Market Growth Strategy
Table 27. Main Points Interviewed from Key Selective Cox-2 Inhibitors Players
Table 28. Global Selective Cox-2 Inhibitors Revenue by Players (2015-2020) (Million US$)
Table 29. Global Selective Cox-2 Inhibitors Market Share by Players (2015-2020)
Table 30. Global Top Selective Cox-2 Inhibitors Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Selective Cox-2 Inhibitors as of 2019)
Table 31. Global Selective Cox-2 Inhibitors by Players Market Concentration Ratio (CR5 and HHI)
Table 32. Key Players Headquarters and Area Served
Table 33. Key Players Selective Cox-2 Inhibitors Product Solution and Service
Table 34. Date of Enter into Selective Cox-2 Inhibitors Market
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 37. Global Selective Cox-2 Inhibitors Market Size Share by Type (2015-2020)
Table 38. Global Selective Cox-2 Inhibitors Revenue Market Share by Type (2021-2026)
Table 39. Global Selective Cox-2 Inhibitors Market Size Share by Application (2015-2020)
Table 40. Global Selective Cox-2 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 41. Global Selective Cox-2 Inhibitors Market Size Share by Application (2021-2026)
Table 42. North America Key Players Selective Cox-2 Inhibitors Revenue (2019-2020) (Million US$)
Table 43. North America Key Players Selective Cox-2 Inhibitors Market Share (2019-2020)
Table 44. North America Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 45. North America Selective Cox-2 Inhibitors Market Share by Type (2015-2020)
Table 46. North America Selective Cox-2 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 47. North America Selective Cox-2 Inhibitors Market Share by Application (2015-2020)
Table 48. Europe Key Players Selective Cox-2 Inhibitors Revenue (2019-2020) (Million US$)
Table 49. Europe Key Players Selective Cox-2 Inhibitors Market Share (2019-2020)
Table 50. Europe Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 51. Europe Selective Cox-2 Inhibitors Market Share by Type (2015-2020)
Table 52. Europe Selective Cox-2 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 53. Europe Selective Cox-2 Inhibitors Market Share by Application (2015-2020)
Table 54. China Key Players Selective Cox-2 Inhibitors Revenue (2019-2020) (Million US$)
Table 55. China Key Players Selective Cox-2 Inhibitors Market Share (2019-2020)
Table 56. China Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 57. China Selective Cox-2 Inhibitors Market Share by Type (2015-2020)
Table 58. China Selective Cox-2 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 59. China Selective Cox-2 Inhibitors Market Share by Application (2015-2020)
Table 60. Japan Key Players Selective Cox-2 Inhibitors Revenue (2019-2020) (Million US$)
Table 61. Japan Key Players Selective Cox-2 Inhibitors Market Share (2019-2020)
Table 62. Japan Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 63. Japan Selective Cox-2 Inhibitors Market Share by Type (2015-2020)
Table 64. Japan Selective Cox-2 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 65. Japan Selective Cox-2 Inhibitors Market Share by Application (2015-2020)
Table 66. Southeast Asia Key Players Selective Cox-2 Inhibitors Revenue (2019-2020) (Million US$)
Table 67. Southeast Asia Key Players Selective Cox-2 Inhibitors Market Share (2019-2020)
Table 68. Southeast Asia Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 69. Southeast Asia Selective Cox-2 Inhibitors Market Share by Type (2015-2020)
Table 70. Southeast Asia Selective Cox-2 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 71. Southeast Asia Selective Cox-2 Inhibitors Market Share by Application (2015-2020)
Table 72. India Key Players Selective Cox-2 Inhibitors Revenue (2019-2020) (Million US$)
Table 73. India Key Players Selective Cox-2 Inhibitors Market Share (2019-2020)
Table 74. India Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 75. India Selective Cox-2 Inhibitors Market Share by Type (2015-2020)
Table 76. India Selective Cox-2 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 77. India Selective Cox-2 Inhibitors Market Share by Application (2015-2020)
Table 78. Central & South America Key Players Selective Cox-2 Inhibitors Revenue (2019-2020) (Million US$)
Table 79. Central & South America Key Players Selective Cox-2 Inhibitors Market Share (2019-2020)
Table 80. Central & South America Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 81. Central & South America Selective Cox-2 Inhibitors Market Share by Type (2015-2020)
Table 82. Central & South America Selective Cox-2 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 83. Central & South America Selective Cox-2 Inhibitors Market Share by Application (2015-2020)
Table 84. Boehringer-Ingelheim Company Details
Table 85. Boehringer-Ingelheim Business Overview
Table 86. Boehringer-Ingelheim Product
Table 87. Boehringer-Ingelheim Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 88. Boehringer-Ingelheim Recent Development
Table 89. TerSera Therapeutics Company Details
Table 90. TerSera Therapeutics Business Overview
Table 91. TerSera Therapeutics Product
Table 92. TerSera Therapeutics Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 93. TerSera Therapeutics Recent Development
Table 94. Iroko Pharmaceuticals Company Details
Table 95. Iroko Pharmaceuticals Business Overview
Table 96. Iroko Pharmaceuticals Product
Table 97. Iroko Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 98. Iroko Pharmaceuticals Recent Development
Table 99. Apotex Company Details
Table 100. Apotex Business Overview
Table 101. Apotex Product
Table 102. Apotex Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 103. Apotex Recent Development
Table 104. Yung Shin Pharmaceutical Company Details
Table 105. Yung Shin Pharmaceutical Business Overview
Table 106. Yung Shin Pharmaceutical Product
Table 107. Yung Shin Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 108. Yung Shin Pharmaceutical Recent Development
Table 109. Breckenridge Pharmaceutical Company Details
Table 110. Breckenridge Pharmaceutical Business Overview
Table 111. Breckenridge Pharmaceutical Product
Table 112. Breckenridge Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 113. Breckenridge Pharmaceutical Recent Development
Table 114. Meda Pharmaceuticals Company Details
Table 115. Meda Pharmaceuticals Business Overview
Table 116. Meda Pharmaceuticals Product
Table 117. Meda Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 118. Meda Pharmaceuticals Recent Development
Table 119. Cipla Business Overview
Table 120. Cipla Product
Table 121. Cipla Company Details
Table 122. Cipla Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 123. Cipla Recent Development
Table 124. Glenmark Pharmaceuticals Company Details
Table 125. Glenmark Pharmaceuticals Business Overview
Table 126. Glenmark Pharmaceuticals Product
Table 127. Glenmark Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 128. Glenmark Pharmaceuticals Recent Development
Table 129. Teva Company Details
Table 130. Teva Business Overview
Table 131. Teva Product
Table 132. Teva Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 133. Teva Recent Development
Table 134. PuraCap Pharmaceutical Company Details
Table 135. PuraCap Pharmaceutical Business Overview
Table 136. PuraCap Pharmaceutical Product
Table 137. PuraCap Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 138. PuraCap Pharmaceutical Recent Development
Table 139. Almirall Limited Company Details
Table 140. Almirall Limited Business Overview
Table 141. Almirall Limited Product
Table 142. Almirall Limited Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 143. Almirall Limited Recent Development
Table 144. Lupin Pharmaceuticals Company Details
Table 145. Lupin Pharmaceuticals Business Overview
Table 146. Lupin Pharmaceuticals Product
Table 147. Lupin Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 148. Lupin Pharmaceuticals Recent Development
Table 149. Aurobindo Pharma Company Details
Table 150. Aurobindo Pharma Business Overview
Table 151. Aurobindo Pharma Product
Table 152. Aurobindo Pharma Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 153. Aurobindo Pharma Recent Development
Table 154. Pfizer Company Details
Table 155. Pfizer Business Overview
Table 156. Pfizer Product
Table 157. Pfizer Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 158. Pfizer Recent Development
Table 159. Mylan Company Details
Table 160. Mylan Business Overview
Table 161. Mylan Product
Table 162. Mylan Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 163. Mylan Recent Development
Table 164. Takeda Company Details
Table 165. Takeda Business Overview
Table 166. Takeda Product
Table 167. Takeda Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 168. Takeda Recent Development
Table 169. Bayer Company Details
Table 170. Bayer Business Overview
Table 171. Bayer Product
Table 172. Bayer Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 173. Bayer Recent Development
Table 174. Novacap Company Details
Table 175. Novacap Business Overview
Table 176. Novacap Product
Table 177. Novacap Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 178. Novacap Recent Development
Table 179. Abbott Company Details
Table 180. Abbott Business Overview
Table 181. Abbott Product
Table 182. Abbott Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 183. Abbott Recent Development
Table 184. Geri-Care Company Details
Table 185. Geri-Care Business Overview
Table 186. Geri-Care Product
Table 187. Geri-Care Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 188. Geri-Care Recent Development
Table 189. Perrigo Company Details
Table 190. Perrigo Business Overview
Table 191. Perrigo Product
Table 192. Perrigo Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 193. Perrigo Recent Development
Table 194. Kopran Company Details
Table 195. Kopran Business Overview
Table 196. Kopran Product
Table 197. Kopran Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 198. Kopran Recent Development
Table 199. Merck Company Details
Table 200. Merck Business Overview
Table 201. Merck Product
Table 202. Merck Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 203. Merck Recent Development
Table 204. Hengrui pharmaceutical Company Details
Table 205. Hengrui pharmaceutical Business Overview
Table 206. Hengrui pharmaceutical Product
Table 207. Hengrui pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 208. Hengrui pharmaceutical Recent Development
Table 209. Kelun Group Company Details
Table 210. Kelun Group Business Overview
Table 211. Kelun Group Product
Table 212. Kelun Group Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 213. Kelun Group Recent Development
Table 214. Qilu Pharmaceutical Company Details
Table 215. Qilu Pharmaceutical Business Overview
Table 216. Qilu Pharmaceutical Product
Table 217. Qilu Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 218. Qilu Pharmaceutical Recent Development
Table 219. Taro Pharmaceuticals Company Details
Table 220. Taro Pharmaceuticals Business Overview
Table 221. Taro Pharmaceuticals Product
Table 222. Taro Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 223. Taro Pharmaceuticals Recent Development
Table 224. Research Programs/Design for This Report
Table 225. Key Data Information from Secondary Sources
Table 226. Key Data Information from Primary Sources
Table 1. Selective Cox-2 Inhibitors Key Market Segments
Table 2. Key Players Covered: Ranking by Selective Cox-2 Inhibitors Revenue
Table 3. Ranking of Global Top Selective Cox-2 Inhibitors Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Selective Cox-2 Inhibitors Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Meloxicam
Table 6. Key Players of Celecoxib
Table 7. Key Players of Etoricoxib
Table 8. Key Players of Imrecoxib
Table 9. Key Players of Etodolac
Table 10. Key Players of Parecoxib
Table 11. Key Players of Other
Table 12. COVID-19 Impact Global Market: (Four Selective Cox-2 Inhibitors Market Size Forecast Scenarios)
Table 13. Opportunities and Trends for Selective Cox-2 Inhibitors Players in the COVID-19 Landscape
Table 14. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 15. Key Regions/Countries Measures against Covid-19 Impact
Table 16. Proposal for Selective Cox-2 Inhibitors Players to Combat Covid-19 Impact
Table 17. Global Selective Cox-2 Inhibitors Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 18. Global Selective Cox-2 Inhibitors Market Size by Regions (US$ Million): 2020 VS 2026
Table 19. Global Selective Cox-2 Inhibitors Market Size by Regions (2015-2020) (US$ Million)
Table 20. Global Selective Cox-2 Inhibitors Market Share by Regions (2015-2020)
Table 21. Global Selective Cox-2 Inhibitors Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 22. Global Selective Cox-2 Inhibitors Market Share by Regions (2021-2026)
Table 23. Market Top Trends
Table 24. Key Drivers: Impact Analysis
Table 25. Key Challenges
Table 26. Selective Cox-2 Inhibitors Market Growth Strategy
Table 27. Main Points Interviewed from Key Selective Cox-2 Inhibitors Players
Table 28. Global Selective Cox-2 Inhibitors Revenue by Players (2015-2020) (Million US$)
Table 29. Global Selective Cox-2 Inhibitors Market Share by Players (2015-2020)
Table 30. Global Top Selective Cox-2 Inhibitors Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Selective Cox-2 Inhibitors as of 2019)
Table 31. Global Selective Cox-2 Inhibitors by Players Market Concentration Ratio (CR5 and HHI)
Table 32. Key Players Headquarters and Area Served
Table 33. Key Players Selective Cox-2 Inhibitors Product Solution and Service
Table 34. Date of Enter into Selective Cox-2 Inhibitors Market
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 37. Global Selective Cox-2 Inhibitors Market Size Share by Type (2015-2020)
Table 38. Global Selective Cox-2 Inhibitors Revenue Market Share by Type (2021-2026)
Table 39. Global Selective Cox-2 Inhibitors Market Size Share by Application (2015-2020)
Table 40. Global Selective Cox-2 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 41. Global Selective Cox-2 Inhibitors Market Size Share by Application (2021-2026)
Table 42. North America Key Players Selective Cox-2 Inhibitors Revenue (2019-2020) (Million US$)
Table 43. North America Key Players Selective Cox-2 Inhibitors Market Share (2019-2020)
Table 44. North America Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 45. North America Selective Cox-2 Inhibitors Market Share by Type (2015-2020)
Table 46. North America Selective Cox-2 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 47. North America Selective Cox-2 Inhibitors Market Share by Application (2015-2020)
Table 48. Europe Key Players Selective Cox-2 Inhibitors Revenue (2019-2020) (Million US$)
Table 49. Europe Key Players Selective Cox-2 Inhibitors Market Share (2019-2020)
Table 50. Europe Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 51. Europe Selective Cox-2 Inhibitors Market Share by Type (2015-2020)
Table 52. Europe Selective Cox-2 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 53. Europe Selective Cox-2 Inhibitors Market Share by Application (2015-2020)
Table 54. China Key Players Selective Cox-2 Inhibitors Revenue (2019-2020) (Million US$)
Table 55. China Key Players Selective Cox-2 Inhibitors Market Share (2019-2020)
Table 56. China Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 57. China Selective Cox-2 Inhibitors Market Share by Type (2015-2020)
Table 58. China Selective Cox-2 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 59. China Selective Cox-2 Inhibitors Market Share by Application (2015-2020)
Table 60. Japan Key Players Selective Cox-2 Inhibitors Revenue (2019-2020) (Million US$)
Table 61. Japan Key Players Selective Cox-2 Inhibitors Market Share (2019-2020)
Table 62. Japan Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 63. Japan Selective Cox-2 Inhibitors Market Share by Type (2015-2020)
Table 64. Japan Selective Cox-2 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 65. Japan Selective Cox-2 Inhibitors Market Share by Application (2015-2020)
Table 66. Southeast Asia Key Players Selective Cox-2 Inhibitors Revenue (2019-2020) (Million US$)
Table 67. Southeast Asia Key Players Selective Cox-2 Inhibitors Market Share (2019-2020)
Table 68. Southeast Asia Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 69. Southeast Asia Selective Cox-2 Inhibitors Market Share by Type (2015-2020)
Table 70. Southeast Asia Selective Cox-2 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 71. Southeast Asia Selective Cox-2 Inhibitors Market Share by Application (2015-2020)
Table 72. India Key Players Selective Cox-2 Inhibitors Revenue (2019-2020) (Million US$)
Table 73. India Key Players Selective Cox-2 Inhibitors Market Share (2019-2020)
Table 74. India Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 75. India Selective Cox-2 Inhibitors Market Share by Type (2015-2020)
Table 76. India Selective Cox-2 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 77. India Selective Cox-2 Inhibitors Market Share by Application (2015-2020)
Table 78. Central & South America Key Players Selective Cox-2 Inhibitors Revenue (2019-2020) (Million US$)
Table 79. Central & South America Key Players Selective Cox-2 Inhibitors Market Share (2019-2020)
Table 80. Central & South America Selective Cox-2 Inhibitors Market Size by Type (2015-2020) (Million US$)
Table 81. Central & South America Selective Cox-2 Inhibitors Market Share by Type (2015-2020)
Table 82. Central & South America Selective Cox-2 Inhibitors Market Size by Application (2015-2020) (Million US$)
Table 83. Central & South America Selective Cox-2 Inhibitors Market Share by Application (2015-2020)
Table 84. Boehringer-Ingelheim Company Details
Table 85. Boehringer-Ingelheim Business Overview
Table 86. Boehringer-Ingelheim Product
Table 87. Boehringer-Ingelheim Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 88. Boehringer-Ingelheim Recent Development
Table 89. TerSera Therapeutics Company Details
Table 90. TerSera Therapeutics Business Overview
Table 91. TerSera Therapeutics Product
Table 92. TerSera Therapeutics Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 93. TerSera Therapeutics Recent Development
Table 94. Iroko Pharmaceuticals Company Details
Table 95. Iroko Pharmaceuticals Business Overview
Table 96. Iroko Pharmaceuticals Product
Table 97. Iroko Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 98. Iroko Pharmaceuticals Recent Development
Table 99. Apotex Company Details
Table 100. Apotex Business Overview
Table 101. Apotex Product
Table 102. Apotex Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 103. Apotex Recent Development
Table 104. Yung Shin Pharmaceutical Company Details
Table 105. Yung Shin Pharmaceutical Business Overview
Table 106. Yung Shin Pharmaceutical Product
Table 107. Yung Shin Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 108. Yung Shin Pharmaceutical Recent Development
Table 109. Breckenridge Pharmaceutical Company Details
Table 110. Breckenridge Pharmaceutical Business Overview
Table 111. Breckenridge Pharmaceutical Product
Table 112. Breckenridge Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 113. Breckenridge Pharmaceutical Recent Development
Table 114. Meda Pharmaceuticals Company Details
Table 115. Meda Pharmaceuticals Business Overview
Table 116. Meda Pharmaceuticals Product
Table 117. Meda Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 118. Meda Pharmaceuticals Recent Development
Table 119. Cipla Business Overview
Table 120. Cipla Product
Table 121. Cipla Company Details
Table 122. Cipla Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 123. Cipla Recent Development
Table 124. Glenmark Pharmaceuticals Company Details
Table 125. Glenmark Pharmaceuticals Business Overview
Table 126. Glenmark Pharmaceuticals Product
Table 127. Glenmark Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 128. Glenmark Pharmaceuticals Recent Development
Table 129. Teva Company Details
Table 130. Teva Business Overview
Table 131. Teva Product
Table 132. Teva Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 133. Teva Recent Development
Table 134. PuraCap Pharmaceutical Company Details
Table 135. PuraCap Pharmaceutical Business Overview
Table 136. PuraCap Pharmaceutical Product
Table 137. PuraCap Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 138. PuraCap Pharmaceutical Recent Development
Table 139. Almirall Limited Company Details
Table 140. Almirall Limited Business Overview
Table 141. Almirall Limited Product
Table 142. Almirall Limited Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 143. Almirall Limited Recent Development
Table 144. Lupin Pharmaceuticals Company Details
Table 145. Lupin Pharmaceuticals Business Overview
Table 146. Lupin Pharmaceuticals Product
Table 147. Lupin Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 148. Lupin Pharmaceuticals Recent Development
Table 149. Aurobindo Pharma Company Details
Table 150. Aurobindo Pharma Business Overview
Table 151. Aurobindo Pharma Product
Table 152. Aurobindo Pharma Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 153. Aurobindo Pharma Recent Development
Table 154. Pfizer Company Details
Table 155. Pfizer Business Overview
Table 156. Pfizer Product
Table 157. Pfizer Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 158. Pfizer Recent Development
Table 159. Mylan Company Details
Table 160. Mylan Business Overview
Table 161. Mylan Product
Table 162. Mylan Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 163. Mylan Recent Development
Table 164. Takeda Company Details
Table 165. Takeda Business Overview
Table 166. Takeda Product
Table 167. Takeda Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 168. Takeda Recent Development
Table 169. Bayer Company Details
Table 170. Bayer Business Overview
Table 171. Bayer Product
Table 172. Bayer Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 173. Bayer Recent Development
Table 174. Novacap Company Details
Table 175. Novacap Business Overview
Table 176. Novacap Product
Table 177. Novacap Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 178. Novacap Recent Development
Table 179. Abbott Company Details
Table 180. Abbott Business Overview
Table 181. Abbott Product
Table 182. Abbott Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 183. Abbott Recent Development
Table 184. Geri-Care Company Details
Table 185. Geri-Care Business Overview
Table 186. Geri-Care Product
Table 187. Geri-Care Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 188. Geri-Care Recent Development
Table 189. Perrigo Company Details
Table 190. Perrigo Business Overview
Table 191. Perrigo Product
Table 192. Perrigo Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 193. Perrigo Recent Development
Table 194. Kopran Company Details
Table 195. Kopran Business Overview
Table 196. Kopran Product
Table 197. Kopran Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 198. Kopran Recent Development
Table 199. Merck Company Details
Table 200. Merck Business Overview
Table 201. Merck Product
Table 202. Merck Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 203. Merck Recent Development
Table 204. Hengrui pharmaceutical Company Details
Table 205. Hengrui pharmaceutical Business Overview
Table 206. Hengrui pharmaceutical Product
Table 207. Hengrui pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 208. Hengrui pharmaceutical Recent Development
Table 209. Kelun Group Company Details
Table 210. Kelun Group Business Overview
Table 211. Kelun Group Product
Table 212. Kelun Group Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 213. Kelun Group Recent Development
Table 214. Qilu Pharmaceutical Company Details
Table 215. Qilu Pharmaceutical Business Overview
Table 216. Qilu Pharmaceutical Product
Table 217. Qilu Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 218. Qilu Pharmaceutical Recent Development
Table 219. Taro Pharmaceuticals Company Details
Table 220. Taro Pharmaceuticals Business Overview
Table 221. Taro Pharmaceuticals Product
Table 222. Taro Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020) (Million US$)
Table 223. Taro Pharmaceuticals Recent Development
Table 224. Research Programs/Design for This Report
Table 225. Key Data Information from Secondary Sources
Table 226. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Selective Cox-2 Inhibitors Market Share by Type: 2020 VS 2026
Figure 2. Meloxicam Features
Figure 3. Celecoxib Features
Figure 4. Etoricoxib Features
Figure 5. Imrecoxib Features
Figure 6. Etodolac Features
Figure 7. Parecoxib Features
Figure 8. Other Features
Figure 9. Global Selective Cox-2 Inhibitors Market Share by Application: 2020 VS 2026
Figure 10. Rheumatoid Arthritis Case Studies
Figure 11. Osteoarthritis Case Studies
Figure 12. Spondylosis Chronica Ankylopoietica Case Studies
Figure 13. Other Case Studies
Figure 14. Selective Cox-2 Inhibitors Report Years Considered
Figure 15. Global Selective Cox-2 Inhibitors Market Size YoY Growth 2015-2026 (US$ Million)
Figure 16. Global Selective Cox-2 Inhibitors Market Share by Regions: 2020 VS 2026
Figure 17. Global Selective Cox-2 Inhibitors Market Share by Regions (2021-2026)
Figure 18. Porter's Five Forces Analysis
Figure 19. Global Selective Cox-2 Inhibitors Market Share by Players in 2019
Figure 20. Global Top Selective Cox-2 Inhibitors Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Selective Cox-2 Inhibitors as of 2019
Figure 21. The Top 10 and 5 Players Market Share by Selective Cox-2 Inhibitors Revenue in 2019
Figure 22. North America Selective Cox-2 Inhibitors Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Europe Selective Cox-2 Inhibitors Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. China Selective Cox-2 Inhibitors Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Japan Selective Cox-2 Inhibitors Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Southeast Asia Selective Cox-2 Inhibitors Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. India Selective Cox-2 Inhibitors Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Central & South America Selective Cox-2 Inhibitors Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Boehringer-Ingelheim Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Boehringer-Ingelheim Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 31. TerSera Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. TerSera Therapeutics Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 33. Iroko Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Iroko Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 35. Apotex Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Apotex Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 37. Yung Shin Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Yung Shin Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 39. Breckenridge Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Breckenridge Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 41. Meda Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Meda Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 43. Cipla Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Cipla Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 45. Glenmark Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Glenmark Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 47. Teva Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Teva Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 49. PuraCap Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. PuraCap Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 51. Almirall Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Almirall Limited Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 53. Lupin Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Lupin Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 55. Aurobindo Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Aurobindo Pharma Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 57. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Pfizer Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 59. Mylan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Mylan Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 61. Takeda Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Takeda Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 63. Bayer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 64. Bayer Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 65. Novacap Total Revenue (US$ Million): 2019 Compared with 2018
Figure 66. Novacap Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 67. Abbott Total Revenue (US$ Million): 2019 Compared with 2018
Figure 68. Abbott Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
Figure 1. Global Selective Cox-2 Inhibitors Market Share by Type: 2020 VS 2026
Figure 2. Meloxicam Features
Figure 3. Celecoxib Features
Figure 4. Etoricoxib Features
Figure 5. Imrecoxib Features
Figure 6. Etodolac Features
Figure 7. Parecoxib Features
Figure 8. Other Features
Figure 9. Global Selective Cox-2 Inhibitors Market Share by Application: 2020 VS 2026
Figure 10. Rheumatoid Arthritis Case Studies
Figure 11. Osteoarthritis Case Studies
Figure 12. Spondylosis Chronica Ankylopoietica Case Studies
Figure 13. Other Case Studies
Figure 14. Selective Cox-2 Inhibitors Report Years Considered
Figure 15. Global Selective Cox-2 Inhibitors Market Size YoY Growth 2015-2026 (US$ Million)
Figure 16. Global Selective Cox-2 Inhibitors Market Share by Regions: 2020 VS 2026
Figure 17. Global Selective Cox-2 Inhibitors Market Share by Regions (2021-2026)
Figure 18. Porter's Five Forces Analysis
Figure 19. Global Selective Cox-2 Inhibitors Market Share by Players in 2019
Figure 20. Global Top Selective Cox-2 Inhibitors Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Selective Cox-2 Inhibitors as of 2019
Figure 21. The Top 10 and 5 Players Market Share by Selective Cox-2 Inhibitors Revenue in 2019
Figure 22. North America Selective Cox-2 Inhibitors Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Europe Selective Cox-2 Inhibitors Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. China Selective Cox-2 Inhibitors Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Japan Selective Cox-2 Inhibitors Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Southeast Asia Selective Cox-2 Inhibitors Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. India Selective Cox-2 Inhibitors Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Central & South America Selective Cox-2 Inhibitors Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Boehringer-Ingelheim Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Boehringer-Ingelheim Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 31. TerSera Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. TerSera Therapeutics Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 33. Iroko Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Iroko Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 35. Apotex Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Apotex Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 37. Yung Shin Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Yung Shin Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 39. Breckenridge Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Breckenridge Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 41. Meda Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Meda Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 43. Cipla Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Cipla Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 45. Glenmark Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Glenmark Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 47. Teva Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Teva Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 49. PuraCap Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. PuraCap Pharmaceutical Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 51. Almirall Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Almirall Limited Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 53. Lupin Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Lupin Pharmaceuticals Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 55. Aurobindo Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Aurobindo Pharma Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 57. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Pfizer Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 59. Mylan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Mylan Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 61. Takeda Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Takeda Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 63. Bayer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 64. Bayer Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 65. Novacap Total Revenue (US$ Million): 2019 Compared with 2018
Figure 66. Novacap Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 67. Abbott Total Revenue (US$ Million): 2019 Compared with 2018
Figure 68. Abbott Revenue Growth Rate in Selective Cox-2 Inhibitors Business (2015-2020)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
